These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 17689352)

  • 1. The children of mama coca: coca, cocaine and the fate of harm reduction in South America.
    Bastos FI; Caiaffa W; Rossi D; Vila M; Malta M
    Int J Drug Policy; 2007 Mar; 18(2):99-106. PubMed ID: 17689352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the efficacy and effectiveness of harm reduction strategies for alcohol, tobacco and illicit drugs.
    Ritter A; Cameron J
    Drug Alcohol Rev; 2006 Nov; 25(6):611-24. PubMed ID: 17132577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supply-side harm reduction strategies: Bolivia's experiment with social control.
    Farthing L; Kohl B
    Int J Drug Policy; 2012 Nov; 23(6):488-94. PubMed ID: 22818891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Illicit traffic and abuse of cocaine.
    Stamler RT; Fahlman RC; Keele SA
    Bull Narc; 1984; 36(2):45-55. PubMed ID: 6569821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug use, harm reduction, and health policies in Argentina: obstacles and new perspectives.
    Inchaurraga S
    Clin Infect Dis; 2003 Dec; 37 Suppl 5():S366-71. PubMed ID: 14648449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malaysia and harm reduction: the challenges and responses.
    Reid G; Kamarulzaman A; Sran SK
    Int J Drug Policy; 2007 Mar; 18(2):136-40. PubMed ID: 17689356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cocaine and heroin markets in the era of globalisation and drug reduction policies.
    Costa Storti C; De Grauwe P
    Int J Drug Policy; 2009 Nov; 20(6):488-96. PubMed ID: 19447024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coca leaf and cocaine addiction--some historical notes.
    Blejer-Prieto H
    Can Med Assoc J; 1965 Sep; 93(13):700-4. PubMed ID: 5318484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disabusing cocaine: pervasive myths and enduring realities of a globalised commodity.
    Dávalos LM; Bejarano AC; Correa HL
    Int J Drug Policy; 2009 Sep; 20(5):381-6. PubMed ID: 19054660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural violence in the context of drug policy and initiatives aiming to reduce drug-related harm in contemporary Brazil: a review.
    Bastos FI
    Subst Use Misuse; 2012; 47(13-14):1603-10. PubMed ID: 23186486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A laboratory approach to the control of cocaine in Bolivia.
    Morales-Vaca M
    Bull Narc; 1984; 36(2):33-43. PubMed ID: 6569820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reduction.
    Hallinan R; Byrne A; Dore GJ
    Drug Alcohol Rev; 2007 Jul; 26(4):437-43. PubMed ID: 17564882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harm reduction, HIV/AIDS, and the human rights challenge to global drug control policy.
    Elliott R; Csete J; Wood E; Kerr T
    Health Hum Rights; 2005; 8(2):104-38. PubMed ID: 17136905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
    Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
    Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The transition to harm reduction: understanding the role of non-governmental organisations in Malaysia.
    Narayanan S; Vicknasingam B; Robson NM
    Int J Drug Policy; 2011 Jul; 22(4):311-7. PubMed ID: 21300533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users.
    Van Den Berg C; Smit C; Van Brussel G; Coutinho R; Prins M;
    Addiction; 2007 Sep; 102(9):1454-62. PubMed ID: 17697278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harm reduction and the global drug control regime: contemporary problems and future prospects.
    Bewley-Taylor DR
    Drug Alcohol Rev; 2004 Dec; 23(4):483-9. PubMed ID: 15763753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harm reduction policies in Argentina: a critical view.
    Epele ME; Pecheny M
    Glob Public Health; 2007; 2(4):342-58. PubMed ID: 19283632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Documenting practices and perceptions of 'safer' crack use: a Canadian pilot study.
    Malchy L; Bungay V; Johnson J
    Int J Drug Policy; 2008 Aug; 19(4):339-41. PubMed ID: 18638705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harm reduction is now the mainstream global drug policy.
    Wodak A
    Addiction; 2009 Mar; 104(3):343-5; discussion 345-6. PubMed ID: 19207340
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.